However, she cautions that after owners demand the change, it’s important they’re involved in allowing people to change the process to decrease risk and make things possible.. Jaimie Johnston points out that people often want innovation, but they want it to be tried and tested, without extra risk.

Pioneering DfMA:.We’re experts in manufacturing-led construction for reduced time and risk.

We analyse where value in.can be leveraged based on experience and knowledge of local markets, and often challenge our partners to question what is possible.. Scalability made simple:.Our approach is to dismantle a process rigorously in order to analyse and optimise every single component, and then combine these into a repeatable, scalable solution.

Digital tools enable us to experiment with a huge number of permutations of components; introducing variables, then measuring, iterating, and refining.This approach ensures maximum flexibility with significant cost and time benefits.Together with Martin Wood, Mark founded Bryden Wood Associates in February 1995.. From 1984-95 Mark had worked with Nicholas Grimshaw's on a collection of the UK’s most influential buildings, a number having become iconic examples of the ‘Hi-tech’ movement.

The 90’s saw significant change in the design and construction industry with the widespread adoption of computer aided design and methods of construction that are now commonplace..

Since 1995, Bryden Wood have sought to maintain and enhance the aspects of the architecture profession that the partners perceived as under threat from commercial pressures, and the emasculation of the profession’s status from overall design led to an aesthetic and often ‘style’ based service.There is a good deal of published research and perspectives on the oversupply of marginally beneficial, or even harmful, drugs..

If we could remove this demand for drugs along with severely reducing the waste of wrongly sold, wrongly prescribed, never-taken and out-of-shelf-life waste, this would have a significant impact on the environmental footprint of the industry.. One of the points raised was the lack of general knowledge about the impact manufacturing and delivery of medicine has on the environment.Greater public awareness may help to reduce some of this wastage through a reduction in demand..

Looking forward, there is a growing dilemma that new modalities may increase the diversity of solvents – acetonitrile, for example, may be of particular concern.The good news is that there is already some strategic collaboration happening in these areas.. As many new medicines are developed by start-ups, if we can ensure good guidance and information then we can get things right from the start.